PRKCA and liver cancer: Midostaurin has inhibitory activity against multiple receptor tyrosine kinases (RTKs), including FLT3, VEGFR, PDGFR, PKCα, c‐KIT et al. Sorafenib is another multi‐kinase inhibitor showing activity against FLT3, VEGFR and PDGFR kinases et al and has been approved for renal and liver cancers.44